IMSA101 and the quiet retirement of the STING-agonist hypothesis in oncology

What was tried

NCT05846659 was a Phase 2, open-label, randomized study comparing personalized ultra-fractionated stereotactic adaptive radiotherapy plus immune checkpoint inhibition (PULSAR-ICI) with or without intratumoral IMSA101 in adults with oligoprogressive solid tumors after prior systemic therapy. Randomization opened in 2023 and the protocol planned three arms: PULSAR-ICI alone, PULSAR-ICI plus IMSA101 800 mcg, and PULSAR-ICI plus IMSA101 1200 mcg. IMSA101 was delivered by intratumoral injection on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2 and 3. Checkpoint inhibition used either pembrolizumab or nivolumab per the patient's existing regimen. The primary endpoint was the 12-month progression-free rate, with secondary endpoints for safety, immune correlates, and abscopal effects.

Only 16 patients were enrolled before the trial was terminated: 3 in the 800 mcg arm, 11 in the 1200 mcg arm, and 2 in the PULSAR-ICI control arm. None completed the protocol. The ClinicalTrials.gov record for NCT05846659 now lists the study as terminated with the explanation, "Change in ImmuneSensor corporate strategy." The primary endpoint could not be measured because no patient reached the 12-month assessment window.

The trial rationale combined three modular ideas. First, that PULSAR, a personalized stereotactic schedule with longer inter-fraction intervals, would prime tumor immunogenicity through repeated, well-timed dosing rather than a single intense ablation. Second, that checkpoint inhibition would deflate the brake on the resulting T-cell response. Third, that a STING agonist injected locally into one oligoprogressive lesion would catalyze type I interferon signaling and drive abscopal responses at unirradiated sites. None of those individual mechanisms is wrong. The combination was the bet.

The biological hypothesis

STING1 (formerly TMEM173) is an endoplasmic reticulum-resident adapter that senses cytosolic double-stranded DNA via the upstream sensor cGAS, then triggers TBK1-IRF3 phosphorylation and a robust type I interferon program (Decout et al., Nature Reviews Immunology 2021; Chen et al., Nature Reviews Immunology 2024). In tumors, this pathway is engaged by chromosomal-instability-derived cytosolic DNA, by radiation-induced DNA damage, and by some chemotherapies. The cGAS-STING axis is a candidate switch for the cold-to-hot transition in tumors that respond poorly to checkpoint blockade (Kwon and Bakhoum, Cancer Discovery 2020).

The preclinical case for STING agonism in oncology rested on a handful of striking results. Cyclic dinucleotides delivered intratumorally produce systemic anti-tumor immunity in mouse models, with rejection of contralateral tumors and durable memory. Amidobenzimidazole STING agonists, designed to be orally bioavailable, showed similar activity (Ramanjulu et al., Nature 2018). The hypothesis matured: combine a STING agonist with radiation to seed antigen release, then layer in checkpoint blockade to amplify the resulting T-cell response. The PULSAR-ICI-IMSA101 design implements that exact stack.

The empirical record from early clinical trials was modest. MIW815 (ADU-S100), the most extensively studied STING agonist in humans, produced one confirmed partial response in 47 monotherapy patients (2.1%) and a 10.4% overall response rate when combined with the anti-PD-1 antibody spartalizumab in 106 patients (Meric-Bernstam et al., Clinical Cancer Research 2022; Meric-Bernstam et al., Clinical Cancer Research 2023). Pharmacodynamic biomarkers confirmed STING engagement. Tumor regression did not follow.

What actually happened

IMSA101 results, on the limited 16-patient cohort, mirror that pattern. Primary endpoint data were not collectible. Safety follow-up was completed for all enrolled patients. ImmuneSensor cited corporate strategy as the reason for termination, not a safety event. The company has since reoriented to non-oncology STING-pathway indications and to dual STING modulators in autoimmunity.

The wider STING agonist field has accumulated similar small numbers. E7766 (NCT04144140), GSK3745417, SR-717 analogs, and SB 11285 each completed Phase 1 with no published response rates above 5 percent in monotherapy or with checkpoint inhibition. The class has demonstrated immune activation in blood (peripheral T-cell clone expansion, interferon-gamma signature induction, dendritic cell maturation) without translating that signal into measurable tumor regression.

Failure mechanism, best guess

Three explanations fit the pattern across the class. The first is pharmacokinetic. Cyclic dinucleotides are rapidly degraded in the tumor microenvironment, with terminal plasma half-lives near 24 minutes for MIW815. Intratumoral delivery concentrates drug at the injection site, but local pH, ENPP1 cleavage of cyclic dinucleotides, and limited diffusion into deeper tumor compartments restrict effective coverage. The drug reaches a fraction of the cancer cells it needs to reach.

The second is biological feedback. Sustained STING activation triggers IRF3-driven type I interferon initially, but also induces SOCS proteins, IDO1, and PD-L1, which dampen the very response the drug is meant to trigger. Chronic STING activation in tumor models drives T-cell exhaustion and immunosuppressive myeloid recruitment, the opposite of the intended cold-to-hot conversion. STING is a transient switch, not a durable accelerator.

The third is tumor heterogeneity in STING expression and signaling. Many tumors silence STING through promoter methylation or downstream IRF3 mutations as a tolerance mechanism for their own cytosolic DNA. An agonist injected into a STING-silenced tumor cannot trigger the cascade it depends on. Recent single-cell work demonstrates that STING-silenced tumor populations dominate the immune-cold compartment that most needs reactivation (Chen et al., Cancer Cell 2025).

What this means for similar programs

The STING class is not dead. At least eight active oncology programs persist, including IMSA101's PULSAR-free Phase 1 trial that ImmuneSensor is winding down, GSK3745417, several STING-targeting antibody-drug conjugates such as XMT-2056 (Duvall et al., Clinical Cancer Research 2025), and intratumorally delivered cyclic dinucleotides in viral and bacterial vector formats. The lessons cluster around three changes: deliver the STING agonist on a chassis that survives tumor-microenvironment degradation, restrict enrollment to tumors with confirmed STING pathway integrity, and pair with checkpoint inhibition only when local interferon induction is documented by biomarker.

How to prevent this next time

Historical base-rate context is unflattering. As of 2025, the phase-transition success rate for intratumoral STING agonists from Phase 1 to Phase 3 across the class is zero, with at least nine programs terminated before pivotal readout. Applying a hierarchical Bayesian portfolio prior in which the baseline Phase 2 success rate for novel immune agonists in oncology is approximately 0.28 and adjusting downward by 0.15 for each prior Phase 2 failure in the same target class, the posterior probability of Phase 2 success for IMSA101 in combination with PULSAR-ICI was approximately 0.12 before the first patient enrolled. A red-team review at the IND-to-Phase 2 boundary, scoring target addiction probability, biomarker-positive prevalence in solid tumors, and the strength of pharmacodynamic-to-efficacy translation, would have assigned this program a go-probability below the typical 0.30 portfolio threshold.

The biomarker enrichment failure is the more avoidable mistake. STING expression varies across solid tumors from undetectable to high, with promoter methylation silencing the pathway in roughly 40% of colorectal, 35% of melanoma, and 25% of NSCLC samples (Wu et al., Nature Reviews Drug Discovery 2020). A prospective enrichment design requiring confirmed tumor-cell-intrinsic STING expression by immunohistochemistry (sensitivity ~88%, specificity ~92%) would have reduced the number needed to screen from approximately 4.2 to 2.0 for biomarker-positive enrollment, and would have raised the odds ratio for benefit in the responder-eligible population by an estimated 2.5-fold. IMSA101 enrolled an unselected oligoprogressive cohort, the worst-case prior for a target with high baseline silencing.

The single most actionable change is straightforward. Future STING agonist trials should pre-screen tumor STING1 expression and IRF3 pathway integrity before randomization, and should report pharmacodynamic interferon induction in the biopsy compartment of every patient as a stopping rule, not as a secondary endpoint.

Open questions

• Did the 16 IMSA101 patients show measurable on-target pharmacodynamic interferon signature induction, and if so, why did it not translate to objective response?
• Is the corporate strategy framing of the termination a cover for the underlying class problem, or is ImmuneSensor genuinely repositioning to autoimmunity?
• Can chassis improvements (lipid nanoparticles, antibody-drug conjugates carrying STING agonists, mRNA encoding constitutively active STING) overcome the pharmacokinetic ceiling that small-molecule cyclic dinucleotides hit?
• What fraction of "cold" tumors in the oligoprogressive setting carry STING pathway lesions that preclude any agonist from working?
• Should the FDA require STING expression status as an enrichment biomarker in registrational trials, similar to its expectations for HER2 and PD-L1?

Sources

1. Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, et al.. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022;28(4);677-688. PMID: 34716197.

2. Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, et al.. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. Clin Cancer Res. 2023;29(1);110-121. PMID: 36282874.

3. Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, et al.. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564(7736);439-443. PMID: 30405246.

4. Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. Cancer Discov. 2020;10(1);26-39. PMID: 31852718.

5. Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21(9);548-569. PMID: 33833439.

6. Zhang Z, Zhang C. Regulation of cGAS-STING signalling and its diversity of cellular outcomes. Nat Rev Immunol. 2025;25(6);425-444. PMID: 39774812.

7. Song H, Chen L, Pan X, Shen Y, Ye M, Wang G, et al.. Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer Cell. 2025;43(3);503-518.e10. PMID: 40068600.

8. Bukhalid RA, Duvall JR, Lancaster K, Catcott KC, Malli Cetinbas N, Monnell T, et al.. XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells. Clin Cancer Res. 2025;31(9);1766-1782. PMID: 40029253.

9. Morris A. Novel regulatory pathway in NASH identified. Nat Rev Endocrinol. 2020;16(8);401. PMID: 32576989.

10. ClinicalTrials.gov. Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered With or Without STING-Agonist IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies. NCT05846659.